Skip to main navigation
Skip to search
Skip to main content
HSC Home
Home
Research units
Profiles
Publications
Sponsored Projects
Core Facilities
Search by expertise, name or affiliation
Alirocumab and cardiovascular outcomes after acute coronary syndrome
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Alirocumab and cardiovascular outcomes after acute coronary syndrome'. Together they form a unique fingerprint.
alirocumab
Medicine & Life Sciences
100%
Acute Coronary Syndrome
Medicine & Life Sciences
59%
Placebos
Medicine & Life Sciences
18%
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Medicine & Life Sciences
13%
LDL Cholesterol
Medicine & Life Sciences
12%
Proprotein Convertase 9
Medicine & Life Sciences
6%
Injection Site Reaction
Medicine & Life Sciences
6%
lipoprotein cholesterol
Medicine & Life Sciences
5%
Cite this